NewsAI-assisted

NeuroBo Transforms into MetaVia Inc.

NeuroBo becomes MetaVia, focusing on MASH and obesity therapies with key trials nearing milestone results.

By Mrudula Kulkarni

Managing Editor - Pharma Now

Nov 19, 2024Updated Jun 26, 2025 · 2 min read

NeuroBo Transforms into MetaVia Inc. — https://www.neurobopharma.com/

AI-assisted reporting

Reviewed by Mrudula Kulkarni, Managing Editor - Pharma Now

NeuroBo Pharmaceuticals, soon to be renamed MetaVia Inc., is realigning its corporate identity to focus on cardiometabolic disease therapies, with the transition effective November 29, 2024. Trading on Nasdaq under the new ticker MTVA, MetaVia aims to highlight its innovative pipeline, including:

DA-1241: A GPR119 agonist for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 2a trial data expected in December 2024.
DA-1726: A dual OXM analog for obesity, with top-line Phase 1 MAD cohort results anticipated in Q1 2025.

MetaVia emphasizes its strong funding foundation and ambition to deliver next-generation treatments.

TopicsNews

Written by

Mrudula Kulkarni

Managing Editor - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.

Discussion

Loading discussion…

NeuroBo Transforms into MetaVia Inc.

Discussion

More from Pharma News

Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting

Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®

Acurx Receives Positive FDA Feedback on Ibezapolstat Phase 3 Development Program, FDA Signals Potential Single-Trial NDA Pathway